RxDoctor Payments Data

Robert Naylor, OD

Optometrist · Hope Mills, NCNPI 1871620922

Payments from drug & device makers

$1,857in general payments, 2019–2025

Across 63 payments — averaging $29.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$610
  • Alcon$415
  • Coopervision Inc.$211
  • Johnson & Johnson Vision Care, Inc.$145
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$135
  • Sun Pharmaceutical Industries Inc.$121
  • plus $220 from 7 others

What the payments were for

  • Food & beverage$1,83399%
  • Entertainment$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,857 in reported general payments places this provider in the 60th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$70,763
Medicare patients
366
Services billed
881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine55$59,023
XiidraLifitegrast29$24,675
CombiganBrimonidine Tartrate/Timolol49$15,818
LumiganBimatoprost16$9,089
Prednisolone Acetate55$1,593
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$1,424
Latanoprost126$1,240
Tobramycin-DexamethasoneTobramycin/Dexamethasone23$1,004
Timolol Maleate66$510
Brimonidine Tartrate16$244
ErythromycinErythromycin Base14$126
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$28$83,930120 claims
Bausch & Lomb Americas Inc.Xiidra$610$24,67529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Hope Mills

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →